The Venture Architecture Diagnostic™
Fourteen work days. Seven deliverables. One structured verdict — with a forward path built in regardless of what the evidence shows.
Every engagement is led personally by Thomas Calvert, end to end. No junior analysts. No delegated delivery. The senior principal is the product.
For organizations that run stage-gates
If your organization already runs stage-gates, the VAD maps directly.
Most CFOs and PMOs already operate in stage-gate language. The VAD verdict schema maps directly — use this bridge rather than asking them to adopt new vocabulary.
| Stage-Gate Term | VAD Verdict |
|---|---|
| Go / Approve | GO |
| Conditional Go | GO with documented autonomy conditions |
| Recycle / Rework | PIVOT |
| Kill | NO-GO |
| Route change / different owner | WRONG COMPANY |
"The VAD is a concentrated Stage 1 gate focused on structural fit — not a replacement for your full financial governance process. It answers the structural question before the financial one locks in."
The distinction between WRONG COMPANY and NO-GO is a $3M decision. Standard stage-gate language collapses that into "kill" and moves on. The VAD does not.
Engagement Options
Thomas reviews your hypothesis, intake materials, and any available internal documentation. You receive a structured diagnostic memo — a single honest answer to the most pressing question your venture is sitting on right now — within three business days. The Quick Scan is not the VAD. It does not produce a full verdict, a Pattern Library entry, or the seven deliverables. It produces one senior-level read and a clear next step.
Your venture is early — pre-sponsor, pre-budget — and you want a structured external read before you invest political capital internally. Or you have one specific structural question that needs an honest answer before you can move forward.
All seven deliverables. Eight analytical streams — RPP structural fit, market intelligence, unit economics modeling, assumption extraction, Black Box bias auditing, stakeholder interview analysis, validation experiment design, and hypothesis stress testing — executed through a structured AI toolkit and synthesized by Thomas personally. Four collaborative check-ins across the sprint — Days 4, 9, 12, and 14. Three mandatory post-sprint outcome tracking calls at 90, 180, and 365 days. The verdict is one of four: GO, PIVOT, WRONG COMPANY, or NO-GO. Every verdict arrives with a named forward path. The Day 14 delivery session is a 60-minute working conversation — not a slide presentation. No ambush on Day 14: hard findings are surfaced progressively at Days 4 and 9 so the verdict, when it lands, is never a surprise.
You have a venture in Stage 0 or early Stage 1, a sponsor identified, and a CFO who needs something more rigorous than internal advocacy before budget commits. The VAD delivers that rigor through a structured AI toolkit administered by a senior practitioner — not a junior analyst team, and not an unsupervised AI tool. You want a verdict you can stand behind — not a recommendation you can negotiate with.
Everything in the Base Sprint, plus a structured internal stakeholder readout deck built specifically for your board, executive team, or investment committee. Most verdicts die in translation. A GO that cannot be communicated convincingly to the CFO does not move capital. A PIVOT framed as failure loses the sponsor. A WRONG COMPANY verdict without a named forward path becomes an indictment rather than a redirection. This tier keeps that from happening.
You know the verdict will trigger a significant internal conversation and you want THC in the room — or the deck — when that conversation happens. Your venture lead has the verdict; the exec team needs to act on it.
Everything in the Base Sprint, plus four hours per month of direct Thomas engagement during the 60-day post-sprint validation window. THC helps you execute the Validation Experiment Playbook, interpret early market signals, and make evidence-based decisions about MVP scope and Stage 2 resource commitment. We do not build the MVP. We help you know whether what you are building is the right thing to build — before the Stage 2 capital commits at scale.
Your venture has received or is likely to receive a GO or structured PIVOT verdict and you want senior advisory continuity through the critical first 60 days of Stage 2. You have a validation plan; you want a senior diagnostic partner to pressure-test it as the evidence comes in.
"The VAD fee is less than 1% of Stage 1 venture capital in a $30M total venture exposure. That is the decision tool inserted before the 90% that follows locks in."
In most corporate venturing portfolios, Stage 1 hypothesis work consumes 3–5% of total venture budget. The VAD fee at $15K–$20K represents less than 1% of a $30M total venture exposure at Stage 1 — before a potential $3–4M Stage 3 commitment locks in.
The Seven Deliverables
Every engagement produces the same seven structured outputs — regardless of verdict.
Sprint Master Report
20–30 pages. Full diagnostic narrative, evidence base, analytical trail, and verdict rationale. Includes the Known Limitations disclosure — named in the report, not hidden in footnotes. The document the venture lead takes into the CFO conversation.
See sample report →RPP Strategic Fit Assessment
Resources, Processes, Priorities alignment scored against an 8-question rubric. Determines whether your organization can host this venture at all — and if so, under what structural conditions. The most predictive single diagnostic in the methodology. At N=128, an RPP score at or below 2 predicts NO-GO or WRONG COMPANY in 96% of cases.
See sample report →Market Intelligence Brief
TAM, SAM, and SOM analysis built on sourced data and adjusted downward from the optimistic top-down estimates internal teams typically present. The number your CFO can defend, not the number that makes the slide look good. Competitive landscape and ecosystem map included.
See sample report →Unit Economics & Financial Model
CAC, LTV, payback period, and reverse P&L across Optimistic, Base Case, and Bear Case scenarios. All three built on bias-calibrated inputs from the Black Box Bias Audit. The model that tells you whether the economics work before you spend $3M finding out they do not.
See sample report →Assumption & Risk Register
Full inventory of every untested assumption in your hypothesis — explicit and implicit — ranked by importance and certainty. Typical output: 30–60 assumptions, including ones the internal team has never stated aloud. The top Critical Unknowns drive the Validation Experiment Playbook.
See sample report →Black Box Bias Audit
A proprietary five-technique adversarial protocol that occupies the space no internal team can fill: the well-informed adversary with no political stake in the outcome. Five techniques: (1) Assumption Extraction — minimum 30–60 assumptions surfaced, 40%+ implicit; (2) Adversarial Probing — every challenge specific, evidence-grounded, and falsifiable; (3) Historical Pattern Matching — at least 3 Pattern Library analogs assessed; (4) Two-Stage Pre-Mortem — failure scenarios generated independently, then walked through with the sponsor on Day 12; (5) Optimism Quantification — base-rate-adjusted model produced alongside the sponsor team's model. The audit runs on structured AI protocols — adversarial prompting at a scale and speed no analyst team replicates at this price point. The differentiator is the practitioner who designed the protocol and interprets what it surfaces. The audit is the proof of it.
See sample report →Validation Experiment Playbook
3–5 prioritized experiments for 30–60-day post-sprint validation. A named agenda for Stage 2 — not a pile of options — with pre-agreed verdict revision triggers built in. If the experiments produce evidence that contradicts the verdict, the playbook names the conditions that would trigger a PIVOT or re-sprint. The engagement does not end at the verdict.
See sample report →Where This Methodology Works Less Well
Every VAD engagement includes a Known Limitations disclosure. The methodology performs less reliably in five specific scenarios. THC names them before the SOW is signed, not after the verdict is delivered.
Two-sided marketplaces
Standard payback math underweights network effects. The VAD will flag structural risks accurately but may underweight the upside of a winner-take-most dynamic.
Regulatory-gated businesses
Where regulatory approval is the primary unknown, the VAD's structural diagnostic is reliable but the timeline and probability modeling carries wider uncertainty bands.
M&A-driven ventures
Where the business model depends on an acquisition that has not yet occurred, the RPP diagnostic evaluates the acquirer's structure, not the target's.
Deep-tech ventures
Where the primary unknown is technical feasibility rather than market or organizational fit, the VAD's market and structural diagnostics are reliable but technology risk requires specialist input.
Radical business-model innovation
Where the venture is attempting to change buyer behavior at a category level, the TAM and CAC calibrations carry wider uncertainty and the Pattern Library analogs are less predictive.